vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $128.6M, roughly 1.6× CorMedix Inc.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $1.1M).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
CRMD vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $200.5M |
| Net Profit | — | $4.5M |
| Gross Margin | 83.4% | 32.2% |
| Operating Margin | 46.0% | — |
| Net Margin | — | 2.2% |
| Revenue YoY | — | 5.2% |
| Net Profit YoY | — | 421.4% |
| EPS (diluted) | $0.20 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $128.6M | $201.5M | ||
| Q3 25 | $104.3M | $216.0M | ||
| Q2 25 | $39.7M | $202.8M | ||
| Q1 25 | $39.1M | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | — | $210.3M | ||
| Q2 24 | — | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $108.6M | $8.6M | ||
| Q2 25 | $19.8M | $-73.6M | ||
| Q1 25 | $20.6M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 83.4% | 31.5% | ||
| Q3 25 | 89.3% | 33.5% | ||
| Q2 25 | 95.3% | 31.6% | ||
| Q1 25 | 95.9% | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 46.0% | 3.5% | ||
| Q3 25 | 49.2% | 7.3% | ||
| Q2 25 | 49.2% | -33.3% | ||
| Q1 25 | 51.5% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 104.1% | 4.0% | ||
| Q2 25 | 49.9% | -36.3% | ||
| Q1 25 | 52.8% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.20 | $0.20 | ||
| Q3 25 | $1.26 | $0.48 | ||
| Q2 25 | $0.28 | $-4.00 | ||
| Q1 25 | $0.30 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | — | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.3M | $1.2B |
| Total Assets | $826.1M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $148.5M | $197.0M | ||
| Q3 25 | $55.7M | $167.8M | ||
| Q2 25 | $190.7M | $157.2M | ||
| Q1 25 | $77.5M | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | — | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $405.3M | $1.2B | ||
| Q3 25 | $374.1M | $1.2B | ||
| Q2 25 | $220.6M | $1.2B | ||
| Q1 25 | $114.9M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $826.1M | $1.4B | ||
| Q3 25 | $750.9M | $1.4B | ||
| Q2 25 | $252.6M | $1.5B | ||
| Q1 25 | $149.6M | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | $5.8M |
| Free Cash FlowOCF − Capex | $92.7M | $1.1M |
| FCF MarginFCF / Revenue | 72.1% | 0.5% |
| Capex IntensityCapex / Revenue | 1.3% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $94.5M | $46.9M | ||
| Q3 25 | $30.9M | $28.9M | ||
| Q2 25 | $30.0M | $13.7M | ||
| Q1 25 | $19.7M | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | — | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $92.7M | $42.2M | ||
| Q3 25 | $30.4M | $21.2M | ||
| Q2 25 | $30.0M | $5.6M | ||
| Q1 25 | $19.7M | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 72.1% | 20.9% | ||
| Q3 25 | 29.1% | 9.8% | ||
| Q2 25 | 75.4% | 2.8% | ||
| Q1 25 | 50.5% | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.3% | 2.3% | ||
| Q3 25 | 0.5% | 3.6% | ||
| Q2 25 | 0.1% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | 0.28× | 3.36× | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
ROG
Segment breakdown not available.
